BioRestorative Therapies Inc (FRA:9OF)

Q3 2025 BioRestorative Therapies Inc Earnings Call Transcript

Nov 12, 2025 / 09:30 PM GMT

Release Date Price: €1.16 (+3.57%)

Transcript 10-Q8-K

Key Points

Positve

BioRestorative Therapies Inc (BRTX) achieved a major milestone with the FDA granting fast track designation for its BRTX 100 program, facilitating a more collaborative approach with the FDA.
The company is nearing completion of enrollment in its phase 2 BRTX 100 clinical trial, which could lead to significant advancements in treating chronic lumbar disc disease.
BioRestorative Therapies Inc (BRTX) has strengthened its commercial infrastructure for its biocosmaceuticals business, including appointing Crystal Romano as the global head of commercial operations.
The company has a strong intellectual property portfolio, with recent patent allowances in Japan for its ThermoStem platform, enhancing protection for its innovative technologies.
BioRestorative Therapies Inc (BRTX) completed a fully subscribed financing round, strengthening its balance sheet and ensuring resources for advancing clinical and commercial milestones.

Negative

BioRestorative Therapies Inc (BRTX) reported a significant year-over-year decrease in Q3 2025 revenues, primarily due to the timing of orders for its biocosmaceutical revenue stream.
The company's net loss increased to $3 million in Q3 2025 from $1 million in the same period of 2024, indicating financial challenges.
There is uncertainty regarding the potential licensing agreement for the ThermoStem metabolic disease program, with no assurances of reaching a mutually acceptable agreement.
The company faces challenges in balancing resources between its clinical development and biocosmaceuticals business, which may impact progress in both areas.
BioRestorative Therapies Inc (BRTX) has not yet dedicated resources to developing its cervical trial, indicating potential delays in expanding its clinical pipeline.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BRTX.OQ - BioRestorative Therapies Inc
Q3 2025 BioRestorative Therapies Inc Earnings Call
Nov 12, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings. Welcome to the bior restorative therapies 3rd quarter 2025 results and business update conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press 0 on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host Stephen Kilmer, Investor relations. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good afternoon

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.